

Minutes of the

2nd Annual General Meeting

of the shareholders of

medmix AG

held on

Friday, 28 April 2023, 10.00 a.m.

at

Lorzensaal, Dorfplatz 3

6330 Cham, Switzerland



The chairman of the Board of Directors (the "**Chairman**"), Grégoire Poux-Guillaume, formally opens the 2nd Annual General Meeting of medmix Ltd at 10.00 a.m. and notes the following:

The invitation to today's Annual General Meeting was published in the Swiss Official Gazette of Commerce on 31 March 2023. This means that the statutory notice period of 20 days has been complied with. The agenda and the proposals were also sent to the shareholders on 31 March 2023.

Pursuant to Art. 699a and Art. 734 of the Swiss Code of Obligations ("**CO**"), the annual report, the compensation report and the auditors' reports must be made available to the shareholders no later than 20 days before the Annual General Meeting. This is the case. The complete annual report, including the compensation report and the auditors' reports, have been available for review and download on medmix' website since 22 February 2023. Furthermore, the resumes of the proposed members of the Board of Directors are available for download on medmix' website.

In advance of the Annual General Meeting, no requests for the inclusion of items on the agenda were received from shareholders, nor were there any proposals or questions regarding items on the agenda.

The meeting is therefore convened in accordance with the law and the articles of association of medmix Ltd. and constitutes a quorum with regard to the published agenda items.

The Chairman welcomes and introduces the members of the Board of Directors attending the meeting. He then welcomes and introduces the members of the Executive Committee as well as the Group General Counsel and Company Secretary, then the heads of functions and business segments. He also welcomes Simon Niklaus, representing KPMG AG, Zurich, as well as Christof Helbling, representing the independent proxy, Proxy Voting Services GmbH.

The Chairman hands over to Christof Helbling. Christof Helbling confirms that, in accordance with Art. 689c para. 5 CO, he has provided the Board of Directors with general information on the voting instructions received from shareholders, no earlier than three working days prior to the Annual General Meeting. This general information included a summary of the yes-votes, no-votes, and abstentions for each agenda item.

The Chairman states that, in accordance with Art. 14 of the articles of association, today's Annual General Meeting is chaired by Grégoire Poux-Guillaume as Chairman. Xavier Schops acts as secretary.

The Chairman then welcomes the vote counters, Gian A. Plattner (UBS Switzerland AG) and Ralph Mooser (Credit Suisse (Switzerland) Ltd) as well as the notary, Linus Schweizer.

The Chairman states that the minutes of last year's Annual General Meeting of 12 April 2022 were duly signed by the Chairman and the Company Secretary and are available for inspection on medmix' website.

The Chairman explains the functioning of the electronic voting devices that the shareholders received. For the vote on the discharge under agenda item 3, the voting devices of those shareholders who are not legally allowed to take part in this vote, have been blocked in the system. With the approval of Tiwel Holding AG, their shares will not be counted on the vote under agenda item 3 either. The Chairman asks the shareholders to participate in a test question to check the functioning of their device.

The Chairman then explains that the Annual General Meeting shall pass resolutions on agenda items 1 to 8 by an absolute majority of the votes represented pursuant to art. 15 para. 1 of the articles of association and on agenda item 9.1 to 9.4 concerning the proposed revision of the articles of association by a two thirds majority of the votes represented pursuant to art. 16 para. 1 of the articles of association in conjunction with art. 704 para. 1 CO.

The Chairman explains where shareholders can register, should they wish to speak during the meeting.

The Chairman points out that the meeting will be recorded on video.

Speech by Girts Cimermans, Chief Executive Officer of medmix Ltd

Girts Cimermans introduces himself and announces that he will present the key highlights of the year 2022. He states the following:

At this Annual General Meeting, medmix looks back at its first complete business year as an independent company. The year was full of new products and commercial success. 2022 was also characterized by unusual and volatile geopolitical and market conditions. Yet, medmix successfully navigated through the year and reached its ambitious milestones. Its long-term customers, its strong business model and the tireless efforts and engagement of medmix' employees made this possible.

medmix closed the financial year 2022 with a revenue of CHF 477 million. This is an increase of 6% compared to the previous year. All segments delivered accelerated revenue growth. As an exception, the Industry segment was impacted by the closure of the plant in Poland, however, Consumer & Industry business area grew by 4%. medmix' strategic growth market, Healthcare, grew by 9% and capitalized on the recovery in scheduled treatments and elective surgeries. Adjusted EBITDA was CHF 105 million, resulting in an adjusted EBITDA margin of 22%. This was driven by higher costs from the relocation of production, ongoing inflationary pressures and the product mix.

medmix has deconsolidated its Polish business and is in discussions to sell its manufacturing operations in Wroclaw, Poland, following the decision made by the Polish government to place medmix Poland under sanctions in April 2022. Since then, medmix is well on its way to recovering its Industry segment sales volumes in the fastest way feasible. medmix has increased production in its plants in Switzerland, the United States and China. Going forward, the Board of Directors does not expect any long-term impact from this issue.

2022 was also a year of global expansion for medmix. A milestone in this journey was securing a site for medmix' future state-of-the-art Healthcare manufacturing facility in Atlanta, USA. Additionally, medmix acquired the plastics business of the Valencia-based Universal de Suministros. medmix' new plant in Valencia, Spain, will further support the Industry segment capabilities in 2023. Lastly, medmix entered into an agreement to acquire a majority stake in Qiaoyi, a Chinese beauty manufacturing business.

In terms of sustainability, medmix committed to the UN Global Compact. medmix acts to achieve the Sustainable Development Goals. In addition, medmix announced last month that it has committed to the Scientific Based Targets adopting the 1.5°C emission goal. medmix has successfully been assessed by CDP, the Carbon Disclosure Project. Separately, medmix has been awarded the best-in-class rating by Eco Vadis.

Looking ahead, the Board of Directors anticipates revenue growth above market rates across each of medmix' segments. This would result in an expected revenue growth range of 5% to 7% in 2023. Adjusted EBITDA margin is expected to reach approximately 23% in 2023. This will be the result of returning to full capacity and a normalized cost base in Industry, as well as an improved revenue mix overall.

medmix' medium-term ambition remains unchanged, with revenue growing at a compound annual growth rate of 8% and an adjusted EBITDA margin of 30%. This increase in profitability will be achieved through a further expanded share of revenue in the more profitable Healthcare business area, as well as an enhancement in operational leverage.

The priorities for 2023 are therefore the continuation on the path to innovation and sustainability, the new plants in Valencia and Atlanta, leveraging the Chinese Beauty acquisition for local-for-local growth and the pursuing of acquisition opportunities where they create strong value.

Girts Cimermans hands back over to the Chairman.

The Chairman states that the Board of Directors has unanimously decided to nominate Rob ten Hoedt as new Chairman. This change comes in the course of the Chairman's appointment as Chief Executive Officer of AkzoNobel last November and the decision not to stand for re-election as Chairman of medmix but to remain, subject to the



shareholders' vote, a regular member of the Board of Directors. Rob ten Hoedt has been a member of the Board of Directors of medmix since 2022 and brings extensive experience in medmix' strategic markets.

The Chairman announces that, at today's Annual General Meeting, 141,204 registered shares are represented by shareholders, whilst 29,067,063 registered shares are represented by the independent proxy. Each registered share has a nominal value of CHF 0.01.

Agenda item 1: ANNUAL REPORT 2022

Agenda item 1.1: BUSINESS REVIEW, FINANCIAL STATEMENTS OF MEDMIX LTD AND CONSOLIDATED FINANCIAL STATEMENTS 2022, REPORTS OF THE AUDITORS

The annual report, containing the business review, the financial statements of medmix Ltd and the consolidated financial statements, as well as the reports of the auditors are available on medmix' website.

The Chairman reiterates the key numbers from the income statement of the holding company, medmix Ltd, for the financial year 2022, starting 1 January 2022, and ending 31 December 2022. The parent company's accounts closed with income of CHF 27.033 million and expenses of CHF 12.763 million, resulting in a net profit of CHF 14.27 million.

The Chairman mentions that medmix Ltd's statutory financial statements have been prepared according to the accounting principles of the Swiss Code of Obligations.

The auditors' reports are included in the "financial section" of the annual report on pages 170 et seqq. (for the consolidated financial statements) and on pages 188 et seqq. (for the financial statements of medmix Ltd). The page numbers refer to the annual reports that can be downloaded in PDF format from the website. The Chairman thanks KPMG AG for their work.

The Chairman states that the representative of KPMG AG, who is present, indicated prior to the Annual General Meeting that he has no additional comment to make on the reports.

The Chairman opens the discussion on this agenda item.

Peter Ulli, Lungern: The speaker asks the Chairman (i) whether medmix has received any compensation for the damages incurred as a result of having to shut down the factory in Poland and (ii) whether the Swiss government has been involved in the discussions with the Polish government.

The Chairman thanks the speaker for his contribution. With regard to the speaker's first question, the Chairman states that medmix has not been compensated. With regard to the speaker's second question, the Chairman explains that the Swiss government was in fact involved and that SECO in particular has been very supportive. The Chairman expresses his frustration that medmix was forced to shut down the factory.

Guido Roethlisberger, Coldrerio: The speaker expresses his frustration that the annual report is available in English only.

The Chairman acknowledges that an annual report in English can be challenging for some investors. He explains that medmix is a global company and, as many other companies in Switzerland, it publishes its annual report in English only for cost and speed reasons.

As there are no further comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Board of Directors proposes that the business review, the financial statements of medmix Ltd and the consolidated financial statements 2022 be approved.

The Chairman announces that the Annual General Meeting approved the business review, the financial statements of medmix Ltd and the consolidated financial statements 2022 with the following results:

Absolute majority	14,604,134
Yes	29,060,916
No	81,087
Abstentions	66,264

The Chairman states that medmix demonstrated a solid performance in 2022 despite challenging conditions. This would not have been possible without the extraordinary performance of medmix' employees. On behalf of the Board of Directors and the Executive Committee, the Chairman thanks all the employees for their great commitment and performance.

Agenda item 1.2: ADVISORY VOTE ON COMPENSATION REPORT 2022

The Chairman explains that agenda item 1.2 is a non-binding advisory vote.

The compensation report sets out the basic principles of medmix' compensation policy and plans, as well as the compensation of the members of the Board of Directors and the Executive Committee. The Chairman further explains the compensation policy of medmix for the Board of Directors and the Executive Committee.

The Chairman opens the discussion on this agenda item. As there are no comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Board of Directors proposes that the compensation report 2022 as set out in the annual report 2022 be approved.

The Chairman announces that the Annual General Meeting approved the compensation report 2022 with the following results:

Absolute majority	14,604,134
Yes	25,539,804
No	3,586,041
Abstentions	82,422

Agenda item 2: APPROPRIATION OF ANNUAL RESULT

The Chairman explains that medmix pursues a dividend policy that takes into account the company's liquidity as well as its economic situation.

The proposal of the Board of Directors includes a gross dividend, before deduction of 35% Swiss withholding tax, of CHF 0.50 per share, payable on 5 May 2023. All shares held by medmix Ltd and its subsidiaries as treasury shares on the record date are not entitled to dividends.

The Chairman opens the discussion on this agenda item. As there are no comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Board of Directors proposes to distribute the total balance of CHF 23,315,045, comprising the net profit for 2022 of CHF 14,269,773, the retained profits of CHF 4,045,272 and the allocation from free reserves of CHF 5,000,000 as follows: CHF 20,457,417 as ordinary dividend and CHF 2,857,628 as carry forward.

The Chairman notes that the Annual General Meeting has approved the appropriation of the annual result proposed by the Board of Directors with the following results:

Absolute majority	14,604,134
Yes	28,237,967
No	940,523
Abstentions	29,777

Agenda item 3: DISCHARGE

The Chairman reminds the shareholders that according to Art. 695 CO, those persons who have participated in the management of the company do not have the right to vote on the present agenda item. With the approval of Tiwel, this restriction is also being applied to the shares held by Tiwel.

The Chairman opens the discussion on this agenda item. As there are no comments from the floor on this agenda item, the Chairman proceeds to the vote on the global discharge of all the members of the Board of Directors and the Executive Committee.

The Board of Directors proposes that discharge be granted to the members of the Board of Directors and the Executive Committee for the financial year 2022.

The Chairman notes that the Annual General Meeting has granted discharge to the Board of Directors and the Executive Committee with the following results:

Absolute majority	6,209,460
Yes	12,287,788
No	68,431
Abstentions	62,699

The Chairman thanks the shareholders for the trust they have placed in the Board of Directors and the Executive Committee.

Agenda item 4: COMPENSATION OF THE MEMBERS OF THE BOARD OF DIRECTORS AND THE EXECUTIVE COMMITTEE

The Chairman comes to the vote on the compensation of the Board of Directors and the Executive Committee. He mentions that agenda item 4 is divided into two sub-items with two separate votes: part 1, "Compensation of the Board of Directors", and part 2, "Compensation of the Executive Committee".

For detailed explanations on the approval of the submitted compensation, the Chairman refers to the "Shareholder information on the compensation votes at the 2023 Annual General Meeting" Report of the Board which shareholders received with the invitation to this Annual General Meeting.

On the compensation of the Board of Directors, the Chairman states that the maximum total amount submitted for approval relates to the remuneration for the term from today's Annual General Meeting to the Annual General Meeting 2024.

The proposed maximum total amount of CHF 1,500,000 is based on the compensation for seven members of the Board of Directors. The members of the medmix Board of Directors receive only a fixed compensation to ensure



their independence. They do not receive any variable or performance-related compensation and are not entitled to participate in medmix' pension plans. The compensation of the Board of Directors is partly paid in cash and partly in restricted stock units (RSU).

On the compensation of the Executive Committee, the Chairman then states that the proposed maximum total amount relates to the compensation for the financial year 2024. He mentions that the Board of Directors has announced its intention to enlarge the Executive Committee to better reflect the growth ambitions of medmix. The proposed amount of CHF 8,500,000 covers the total compensation of the members of the enlarged Executive Committee. The total compensation consists of a fixed base salary and a variable component. The variable component comprises a short-term performance-related bonus (in cash) and a long-term performance-related performance share unit (PSU) plan. This system is designed to motivate above-average performance and to recognize this performance accordingly.

The Chairman mentions that this is a maximum amount. In accordance with legal requirements, the calculation of the maximum total amount of compensation for the Executive Board takes into account the potential maximum amounts under the variable component of compensation, *i.e.*, both the short-term and long-term incentive systems.

The compensation actually paid out will be disclosed in the compensation report for the financial year 2024 which is submitted to the shareholders for a consultative vote.

The Chairman opens the discussion on this agenda item. As there are no comments from the floor on this agenda item, the Chairman proceeds to the votes.

Agenda item 4.1: COMPENSATION OF THE BOARD OF DIRECTORS

The Annual General Meeting votes on the approval of the total amount for the remuneration of the Board of Directors for the term from the Annual General Meeting 2023 until the end of the Annual General Meeting 2024 in the maximum amount of CHF 1,500,000.

The Chairman notes that the Annual General Meeting approved the maximum total compensation of the Board of Directors for the term from the Annual General Meeting 2023 until the end of the Annual General Meeting 2024 with the following results:

Absolute majority	14,604,134
Yes	28,391,792
No	741,891
Abstentions	74,584

Agenda item 4.2: COMPENSATION OF THE EXECUTIVE COMMITTEE

The Chairman continues with the vote on agenda item 4.2:

The Annual General Meeting votes on the approval of the total amount for the compensation of the Executive Committee for the financial year 2024 in the maximum amount of CHF 8,500,000.

The Chairman notes that the Annual General Meeting has approved the maximum total compensation of the Executive Committee for the financial year 2024 with the following results:

Absolute majority	14,604,134
Yes	27,877,964
No	1,251,309
Abstentions	78,994

Agenda item 5: ELECTION OF THE BOARD OF DIRECTORS

The Chairman mentions that agenda item 5 is divided into two sub-items with separate votes, namely agenda item 5.1 "Election of the Chairman of the Board of Directors" and agenda item 5.2 "Re-election of Board Members".

Agenda item 5.1: ELECTION OF THE CHAIRMAN OF THE BOARD OF DIRECTORS

The Chairman explains that he does not stand for re-election as Chairman. Instead, Rob ten Hoedt has been proposed by the Board of Directors for re-election as a member of the Board as well as for election as new Chairman.

The Chairman explains that Rob ten Hoedt is a Dutch national who has been living and working in Switzerland since 2006. He spent most of his career with Medtronic, one of the world's largest medical devices companies. He is currently the Executive Vice President and President, Global regions for Medtronic.

Rob ten Hoedt has gained more than 30 years of experience in the medical devices industry in a broad variety of roles, including sales, marketing, and general management.

A member of the Board of Directors of medmix since 2022, Rob ten Hoedt is currently the chairman of medmix' Nomination & Remuneration Committee. He studied in the Netherlands and graduated with a Degree in Commercial Economy and a master's in marketing.

As Rob ten Hoedt is not able to attend the Annual General Meeting in person, a video of Rob ten Hoedt is played in which he introduces himself to the shareholders.

The Chairman opens the discussion on this agenda item. As there are no comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Board of Directors proposes that the shareholders re-elect Rob ten Hoedt as member of the Board of Directors and elect him as Chairman of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman announces that the Annual General Meeting has elected Rob ten Hoedt as Chairman and re-elected him as member of the Board of Directors with the following results:

Absolute majority	14,604,134
Yes	23,560,533
No	5,595,781
Abstentions	51,953

The Chairman congratulates Rob ten Hoedt on his election.

Agenda item 5.2: RE-ELECTIONS

On the re-election of the current members of the Board of Directors, the Chairman states the following:

The Board of Directors of medmix consists of seven individuals with an international and diverse background.

The Board of Directors supports the re-election of all current members who are standing for re-election, that is Marco Musetti, Barbara Angehrn, René Willi, Daniel Flammer, David Metzger and Grégoire Poux-Guillaume.

Marco Musetti has been elected as member of the Board of Directors at the Annual General Meeting 2021. He is vice-chairman of the Board of Directors and chairman of the Audit Committee.

Marco Musetti has been a member of the Board of Directors at several international companies and was also a member of the Board of Directors of Sulzer Ltd from 2011 to April 2021. Previously, he was COO and deputy CEO of Aluminum Silicon Marketing (Sual Group), Head of Metals and Structured Finance Desk for Banque Cantonale Vaudoise, and Deputy Head of Metals Desk for Banque Bruxelles Lambert.

The Chairman hands over to Marco Musetti.

Marco Musetti explains that **Grégoire Poux-Guillaume** has been elected as member and Chairman at the Annual General Meeting 2021 and has been confirmed as Chairman at the Annual General Meeting 2022. He is currently a member of the Nomination & Remuneration Committee. He does not stand for re-election as Chairman but has agreed to stay on as ordinary member of the Board of Directors since, as former CEO of the Sulzer group, he has an in-depth knowledge of medmix.

Marco Musetti hands back over to the Chairman. The Chairman states the following:

Barbara Angehrn has been elected as member of the Board of Directors at the Annual General Meeting 2022. She is a member of the Nomination & Remuneration Committee. Barbara Angehrn was a member of the Executive Committee of Vifor Pharma (acquired in August 2021 by CSL), initially as Chief Business & Marketing Officer, responsible for all Global Commercial Functions as well as the overall Nephrology portfolio, then as Chief Business & Operating Officer with responsibility for the Technical Operations, Manufacturing, IT and other Corporate functions.

René Willi has been elected as member of the Board of Directors at the Annual General Meeting 2022. He is a member of the Audit Committee. Since 2021, René Will has been Chief Executive Officer of the Global Oral Reconstruction Group at Henry Schein Inc. and a member of the Henry Schein Inc. Executive Management Committee.

Daniel Flammer has been elected as member of the Board of Directors at the Annual General Meeting 2022. He is a member of the Audit Committee. Daniel Flammer has been Managing Partner of AR Financial Advisory AG in Zurich since April 2018 where he provides transaction advisory and CFO advisory services.

David Metzger has been elected as member of the Board of Directors in 2022. David Metzger is currently working for Liwet Holding AG. Previously, he was Investment Director at Good Energies AG, Senior Manager at Bain & Company, and has also worked at Novartis and Morgan Stanley.

The Chairman opens the discussion on this agenda item. As there are no comments from the floor on this agenda item, the Chairman proceeds to the elections.

The Chairman starts with the re-election of Marco Musetti under agenda item 5.2.1. The Board of Directors proposes the re-election of Marco Musetti as member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Marco Musetti to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Absolute majority	14,604,134
Yes	26,092,760
No	3,063,007
Abstentions	52,500

Marco Musetti takes over and continues with the re-election of Grégoire Poux-Guillaume under agenda item 5.2.2. The Board of Directors proposes to re-elect Grégoire Poux-Guillaume as member of the Board of Directors for a term until the end of the next Annual General Meeting. Marco Musetti hands back over to the Chairman.

The Chairman notes that the Annual General Meeting has re-elected him to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Absolute majority	14,604,134
Yes	27,733,739
No	1,422,706
Abstentions	51,822

The Chairman continues with the re-election of Barbara Angehrn under agenda item 5.2.3. The Board of Directors proposes to re-elect Barbara Angehrn as member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Barbara Angehrn to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Absolute majority	14,604,134
Yes	29,042,171
No	115,319
Abstentions	50,777

The Chairman continues with the re-election of René Willi under agenda item 5.2.4. The Board of Directors proposes the re-election of René Willi as member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected René Willi to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Absolute majority	14,604,134
Yes	29,090,884
No	65,673
Abstentions	51,710

The Chairman continues with the re-election of Daniel Flammer under agenda item 5.2.5. The Board of Directors proposes to re-elect Daniel Flammer as member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Daniel Flammer to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Absolute majority	14,604,134
Yes	25,058,528
No	4,093,909
Abstentions	55,830

The Chairman continues with the re-election of David Metzger under agenda item 5.2.6. The Board of Directors proposes to re-elect David Metzger as member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected David Metzger to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Absolute majority	14,604,134
Yes	26,707,118

No	2,442,614
Abstentions	58,535

The Chairman mentions that the Board of Directors will be reconstituted following the Annual General Meeting and that the relevant decisions will be published. This concerns the election of the vice-chairperson of the Board of Directors, the election of the chairperson of the Nomination & Remuneration Committee, as well as the election and constitution of the Audit Committee, *i.e.*, the election of the members and the chairperson.

Agenda item 6: ELECTION OF THE NOMINATION & REMUNERATION COMMITTEE

Agenda item 6.1: RE-ELECTION

The Chairman mentions that he does not stand for re-election to the Nomination & Remuneration Committee. The Board of Directors proposes that the shareholders re-elect Barbara Angehrn and Rob ten Hoedt as members of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting. Both, Barbara Angehrn and Rob ten Hoedt joined the Nomination & Remuneration Committee in 2022.

The Chairman opens the discussion on this agenda item.

Viviana Giovannozzi, Zug: The speaker expresses her frustration regarding the lack of diversity on medmix' Board of Directors. Prompted, she defines diversity as relative to gender and countries of origin. She states that she is, however, pleased to see that the Executive Committee is very diverse.

The Chairman confirms that diversity is an important topic for medmix. He explains that two out of three members of the Executive Committee are women. He states that there is only one woman on the Board of Directors, which is a topic that medmix will need to address. The Chairman highlights the international backgrounds of the members of the Board of Directors, which refutes any notion of lack of diversity in terms of countries of origin. He closes his remarks by pointing out that diversity is also one of the topics the proxy advisors base their voting recommendations on.

As there are no further comments from the floor on this agenda item, the Chairman proceeds to the vote. The Board of Directors proposes to re-elect Barbara Angehrn as member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Barbara Angehrn as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting with the following results:

Absolute majority	14,604,134
Yes	28,942,068
No	214,805
Abstentions	51,394

The Chairman continues with the re-election of Rob ten Hoedt under agenda item 6.1.2. The Board of Directors proposes to re-elect Rob ten Hoedt as member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Rob ten Hoedt as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting with the following results:

Absolute majority	14,604,134
Yes	22,108,290
No	7,045,918
Abstentions	54,059

Agenda item 6.2: ELECTION OF A NEW MEMBER

The Chairman continues with the election of a new member of the Nomination & Remuneration Committee under agenda item 6.2. The Board of Directors proposes that the shareholders elect David Metzger as new member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting. David Metzger has been elected to the Board of Directors in 2022 and has been re-elected today.

The Chairman opens the discussion on this agenda item. As there are no comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Chairman notes that the Annual General Meeting has elected David Metzger as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting with the following results:

Absolute majority	14,604,134
Yes	25,081,471
No	4,057,900
Abstentions	68,896

Agenda item 7: RE-ELECTION OF AUDITORS

The Chairman continues with the re-election of the auditors.

The Board of Directors proposes that KPMG AG, Zurich, be re-elected as auditors.

The Chairman opens the discussion on this agenda item. As there are no comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Chairman notes that the Annual General Meeting has re-elected KPMG AG as auditors with the following results:

Absolute majority	14,604,134
Yes	29,066,938
No	91,069
Abstentions	50,260

Agenda item 8: RE-ELECTION OF INDEPENDENT PROXY

The Chairman continues with the re-election of the independent proxy under agenda item 8.

The Board of Directors proposes to re-elect Proxy Voting Services GmbH, Zurich, as independent proxy for a term until the end of the next Annual General Meeting. Proxy Voting Services GmbH meets the requirements for independence. It is not connected to medmix through any other activities.

The Chairman opens the discussion on this agenda item. As there are no comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Chairman notes that the Annual General Meeting has re-elected Proxy Voting Services GmbH as independent proxy for a term until the end of the next Annual General Meeting with the following results:

Absolute majority	14,604,134
Yes	29,141,437
No	16,223
Abstentions	50,607

Agenda item 9: REVISION OF THE ARTICLES OF ASSOCIATION

The Chairman comes to the last agenda item, the revision of the articles of association under agenda item 9.

The Chairman explains that on 19 June 2020, the Swiss Parliament adopted a revision of the corporate law, which entered into force on 1 January 2023. The Corporate Law Reform primarily aims to modernize Swiss corporate law and strengthen shareholder rights. The new Swiss corporate law provides for a transitional period of two years during which Swiss companies have to amend their corporate documents to reflect the changes in the law. Accordingly, the Board of Directors proposes to the shareholders to revise the articles of association at today's Annual General Meeting. In addition, the Board of Directors took this opportunity to propose a few additional updates to the articles of association.

All amendments to the articles of association have been outlined in the "Report of the Board of Directors on the Revision of the Articles of Association", which has been distributed to all shareholders together with the invitation for the Annual General Meeting. The Chairman therefore assumes that the proposed amendments to the articles of association are known to the General Meeting participants and will therefore neither read out the provisions of the articles of association individually nor project them on the screen.

Agenda item 9 is divided into 4 sub-items with 4 separate votes.

Under agenda item 9.1, votes will be taken on amending the purpose of the company; under agenda item 9.2, the Board of Directors compiled amendments on the shares and the share register; under agenda item 9.3, the Board of Directors compiled changes on shareholder rights, the Annual General Meeting, reserves, the publication organ as well as notifications; and finally, under agenda item 9.4, amendments relating to the Board of Directors, compensation, contracts with members of the Board of Directors and the Executive Committee as well as mandates outside the Group are compiled. The Chairman notes that the amendments under agenda item 9 require a qualified majority of at least two thirds of the votes represented at the Annual General Meeting.

The Chairman opens the discussion on agenda item 9.1 to 9.4. As there are no comments from the floor on these agenda items, the Chairman proceeds to the votes.

The Chairman begins with the vote under agenda item 9.1. The Board of Directors proposes to approve the amendments to article 2 of the articles of association according to section B.1 of the report of the Board of Directors.

The Chairman notes that the Annual General Meeting has approved the proposed change of the articles of association with the following results:

Qualified majority	19,472,178
Yes	29,098,387
No	57,130
Abstentions	52,750

The Chairman asks the notary to certify this result.



The Chairman continues with the vote under agenda item 9.2. The Board of Directors proposes to approve the amendments to articles 4, 6 and 6a of the articles of association according to section B.2 of the report of the Board of Directors.

The Chairman notes that the Annual General Meeting has approved the proposed change of the articles of association with the following results:

Qualified majority	19,472,178
Yes	29,059,839
No	80,495
Abstentions	67,933

The Chairman asks the notary to certify this result.

The Chairman continues with the vote under agenda item 9.3. The Board of Directors proposes to approve the amendments to articles 7, 12, 14, 15, 16, 17, 36 and 38 of the articles of association according to section B.3 of the report of the Board of Directors.

The Chairman notes that the Annual General Meeting has approved the proposed change of the articles of association with the following results:

Qualified majority	19,472,178
Yes	26,758,570
No	2,392,362
Abstentions	57,335

The Chairman asks the notary to certify this result.

The Chairman continues with the vote under agenda item 9.4. The Board of Directors proposes to approve the amendments to articles 18, 19, 21, 22, 30, 32 and 33 of the articles of association according to section B.3 of the report of the Board of Directors.

The Chairman notes that the Annual General Meeting has approved the proposed change of the articles of association with the following results:

Qualified majority	19,472,178
Yes	29,064,211
No	75,804
Abstentions	68,252

The Chairman asks the notary to certify this result.

The Chairman closes this year's Annual General Meeting. He thanks the shareholders for their interest and invites them to a reception.

Closing of the meeting: 11:15 a.m.



The Chairman:



Grégoire Poux-Guillaume

The Secretary:



Xavier Schops